Charcot Marie Tooth disease (CMT) is the eponym for heritable peripheral neuropathy. CMT affects approximately 1 in 2500 people and is divisible into three large sub-groups;CMT1 (dominantly inherited demyelinating neuropathies), CMT2 (dominantly inherited axonal neuropathies), and CMT4 (recessively inherited neuropathies). Mutations in more than 70 genes cause CMT1, CMT2 and CMT4. The biological basis for demyelination and axonal degeneration in these disorders has enabled rational therapy development for some kinds of CMT. Clinical trials, however, have been limited by a combination of a lack of natural history data, a lack of outcome measures that are sensitive to change in a short period, and a lack of outcome measures for young children with CMT. We have enrolled over 4200 patients into the protocols of the Inherited Neuropathy Consortium (INC) during our first cycle in the RDCRN. Support from our patient advocacy groups (PAGs) has allowed us to expand from 6 to 15 sites within the INC. Additional support from NINDS allowed us to develop the CMT-lnternational Database (CMT-ID), a group of national CMT registries who also use the CMT Minimal Dataset and house their data at the DMCC. Taking these together, we have a unique opportunity to obtain and evaluate patients with rare forms of inherited neuropathy. We propose to extend our work over the next 5 years with the following Specific Aims:
Aim 1 : Expand natural history investigations on CMT1A, CMT1B, CMT1X and CMT2A.
Aim 2 : Accrue and evaluate patients with rare forms of CMT.
Aim 3 : Validate and test patient reported disability and QOL instruments in adults with CMT.
Aim 4 : Validate infant-toddler disability and QOL instruments in children with CMT.
TO THE INC RDCRC Developing outcome instruments that measure disease progression in a manner that is relevant to people afflicted with inherited peripheral neuropathies is one of the main goals of the Inherited Neuropathy Consortium (INC). Because these disorders are rare these studies can only be performed in a consortium of trained expert clinical investigators such as those in the INC.
|Dortch, Richard D; Dethrage, Lindsey M; Gore, John C et al. (2014) Proximal nerve magnetization transfer MRI relates to disability in Charcot-Marie-Tooth diseases. Neurology 83:1545-53|
|Brewer, Megan Hwa; Ma, Ki Hwan; Beecham, Gary W et al. (2014) Haplotype-specific modulation of a SOX10/CREB response element at the Charcot-Marie-Tooth disease type 4C locus SH3TC2. Hum Mol Genet 23:5171-87|
|Lam, Byron L; Züchner, Stephan L; Dallman, Julia et al. (2014) Mutation K42E in dehydrodolichol diphosphate synthase (DHDDS) causes recessive retinitis pigmentosa. Adv Exp Med Biol 801:165-70|
|Finkel, Richard S; McDermott, Michael P; Kaufmann, Petra et al. (2014) Observational study of spinal muscular atrophy type I and implications for clinical trials. Neurology 83:810-7|
|Liu, Yo-Tsen; Laurá, Matilde; Hersheson, Joshua et al. (2014) Extended phenotypic spectrum of KIF5A mutations: From spastic paraplegia to axonal neuropathy. Neurology 83:612-9|
|Mudge, Anita J; Bau, Karen V; Purcell, Leanne N et al. (2014) Normative reference values for lower limb joint range, bone torsion, and alignment in children aged 4-16 years. J Pediatr Orthop B 23:15-25|
|Foley, A Reghan; Menezes, Manoj P; Pandraud, Amelie et al. (2014) Treatable childhood neuronopathy caused by mutations in riboflavin transporter RFVT2. Brain 137:44-56|
|Ramchandren, Sindhu; Jaiswal, Mamta; Feldman, Eva et al. (2014) Effect of pain in pediatric inherited neuropathies. Neurology 82:793-7|
|Wen, Rong; Dallman, Julia E; Li, Yiwen et al. (2014) Knock-down DHDDS expression induces photoreceptor degeneration in zebrafish. Adv Exp Med Biol 801:543-50|
|Griffin, Laurie B; Sakaguchi, Reiko; McGuigan, David et al. (2014) Impaired function is a common feature of neuropathy-associated glycyl-tRNA synthetase mutations. Hum Mutat 35:1363-71|
Showing the most recent 10 out of 53 publications